What is Evox Therapeutics?
Founded in 2016, Evox Therapeutics is a biotechnology company headquartered in Oxford, England, dedicated to the development of novel exosome-based therapeutics. The company utilizes its proprietary DeliverEX platform to engineer exosomes—naturally occurring extracellular vesicles—to transport complex drug payloads to specific tissues and cells. This approach offers a transformative solution for treating rare and severe diseases that have historically lacked effective therapeutic interventions. By focusing on the precision delivery of proteins, nucleic acids, and small molecules, Evox is establishing a dominant market position within the next-generation drug delivery sector, effectively scaling its operations to meet the demands of global healthcare markets.
How much funding has Evox Therapeutics raised?
Evox Therapeutics has raised a total of $142.7M across 3 funding rounds:
Grant
$1.1M
Series B
$46.2M
Series C
$95.4M
Grant (2019): $1.1M with participation from Innovate UK
Series B (2020): $46.2M led by Redmile Group , LLC, Google Ventures, Oxford University, Cowen Healthcare Investments, Panacea Healthcare Venture, Oxford Sciences Innovation, and Borealis Ventures
Series C (2021): $95.4M supported by OrbiMed, Cowen Healthcare Investments, Redmile Group, Invus, Oxford Sciences Innovation, and GV
Key Investors in Evox Therapeutics
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on life sciences and frontier technology innovations.
Oxford Science Enterprises
Oxford Science Enterprises is an independent investment company created to found, fund and build transformational businesses via a unique partnership with the University of Oxford.
What's next for Evox Therapeutics?
Looking ahead, the strategic deployment of the $95.4M will likely focus on advancing the company's lead candidates through clinical trials and further refining its exosome engineering capabilities. As Evox Therapeutics transitions from a research-heavy entity to a clinical-stage powerhouse, the focus will shift toward establishing manufacturing scalability and forging strategic partnerships with global pharmaceutical leaders. The company's ability to maintain a robust investor syndicate, including top-tier venture capital firms and academic-linked investment vehicles, suggests a clear path toward commercialization and long-term value creation in the competitive biotechnology landscape.
See full Evox Therapeutics company page
